ArticleCureus2025
Prostatic Metastasis of Bilateral Metachronous Testicular Cancer: A Case Report and Review of the Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular cancer is an uncommon malignancy that primarily affects young men. Most cases are germ cell tumors (GCTs), which may present as seminomatous or non-seminomatous types. Bilateral occurrence is unusual, often developing at different times. Typical metastatic sites include retroperitoneal lymph nodes, lungs, and mediastinum, whereas prostate involvement is exceptionally uncommon. We report a 39-year-old man with a history of bilateral, metachronous testicular cancer treated initially with orchiectomy and chemotherapy for a right-sided mixed GCT, followed by orchiectomy for a left-sided non-seminomatous germ cell tumor (NSGCT). He presented seven years later with urinary symptoms, elevated tumor markers, and imaging that revealed a large pelvic mass infiltrating the prostate, seminal vesicles, and left ureter. Biopsy confirmed metastatic NSGCT with elements of embryonal carcinoma, teratoma, and yolk sac tumor. Classified as poor prognosis by the International Germ Cell Cancer Collaborative Group (IGCCCG), he underwent salvage chemotherapy with ifosfamide, paclitaxel, and cisplatin (TIP), followed by radical cystoprostatectomy with pelvic exenteration. At six months post treatment, he remained disease-free with normalized tumor markers. Prostate metastasis from testicular GCTs is an extremely rare event, especially following bilateral, metachronous primaries. This case is unique in demonstrating recurrence with histological elements from both tumors. Aggressive multimodal treatment with TIP, followed by pelvic exenteration, achieved radiological and biochemical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.